RAF1 and neoplasm: MEK1/2 (MAP2K1/K2), the canonical targets of MEK inhibitors, are dual-specificity threonine/tyrosine kinases that are integral in the activation of the RAS/RAF/MEK/ERK pathway and are often upregulated in a variety of tumor cell types.